Jul 28
|
Merck & Co., Inc.'s (NYSE:MRK) Dismal Stock Performance Reflects Weak Fundamentals
|
Jul 26
|
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
|
Jul 24
|
MSD reports positive topline data from Phase IIb/III RSV trial in infants
|
Jul 23
|
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
|
Jul 23
|
Merck Announces Fourth-Quarter 2024 Dividend
|
Jul 23
|
Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?
|
Jul 23
|
Billionaires Are Loading Up on This Surging Dow Stock. Should You?
|
Jul 23
|
Merck & Co., Inc. (NYSE:MRK) is largely controlled by institutional shareholders who own 78% of the company
|
Jul 23
|
Merck claims late-stage study success for RSV antibody
|
Jul 23
|
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
|
Jun 25
|
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
|
Jun 25
|
ASCO24: MSD’s ADC shows efficacy in lung and breast tumours
|
Jun 24
|
Merck (MRK) Increases Despite Market Slip: Here's What You Need to Know
|
Jun 24
|
Is Merck & Co., Inc. (MRK) a Strong Buy Right Now?
|
Jun 22
|
With 78% ownership of the shares, Merck & Co., Inc. (NYSE:MRK) is heavily dominated by institutional owners
|
Jun 21
|
The 30-stock secret: ‘Don’t fight Papa Dow’
|
Jun 20
|
Merck Is Partnering With America’s Largest HBCU To Launch a Collaborative Biotechnology Learning Center
|
Apr 7
|
10 Best Weight Loss Drug Stocks to Buy Now
|
Apr 6
|
The three-year decline in earnings for Merck NYSE:MRK) isn't encouraging, but shareholders are still up 93% over that period
|
Apr 5
|
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
|